Amicus Therapeutics: Dedication to Healing Beyond Atypical Diseases

Based in Cranbury, New Jersey, Amicus Therapeutics is a global biopharmaceutical corporation founded in February of 2002. By 2008 had gone public and had also expanded from their initial New Jersey site to a new facility in San Diego, California. In 2010, the organization received two substantial grants from the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation for collaborative studies and pre-clinical work with UCLA’s David Geffen School of Medicine and the Icahn School of Medicine at Mount Sinai, respectively. Amicus Therapeutics prides itself on being the spearhead of advanced therapeutic treatments for a wide variety of devastating uncommon diseases, specifically related to irregularities that are commonly known as Lysosomal Storage Disorders, and boast having a resilient developmental conduit of treatments for an assortment of human genetic diseases. In the year 2014, Amicus Therapeutics was renowned for conceivably possessing “the broadest portfolio of small molecule pharmacological chaperones” in the pharmaceutical industry (Crunchbase).

The patients matter, and it shows through their dedication to developing more up-to-date, superior therapy options to chose from in battling each of these disorders. Amicus Therapeutics is constantly striving to expound upon their list of treatments in hopes of assisting a wider scope of these diseases, and supporting those who suffer through them. The organization is passionate about providing aid and assistance with helpful, real-life implementations to help those who suffer from these disorders and cope with the daily struggles that they bring. The corporation uses their experiences and interactions with their patients and those affected by their illnesses to constantly improve and find new and better options for their clinical trials (http://www.marketwatch.com/investing/stock/fold). Amicus Therapeutics’ mission statement, in a paraphrased summary, states that they strive to remain a leader in therapeutic treatment of infrequent and orphan diseases, to build long-term value for their shareholders, and always encourage a united work-front and respect for each team member and what they bring to the company. Their dedication to each and every patient, those patient’s families, and their own team members is what leads their ability to provide healing beyond the disease.

Comments are closed.